Epithelial ovarian cancer
Information
- Disease name
- Epithelial ovarian cancer
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02124421 | Active, not recruiting | Phase 2 | HOT: HIPEC in Ovarian Cancer as Initial Treatment | April 2014 | April 2028 |
| NCT04209855 | Active, not recruiting | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | December 31, 2019 | April 2024 |
| NCT01276574 | Active, not recruiting | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT | October 2009 | December 31, 2024 | |
| NCT04902872 | Active, not recruiting | Phase 1/Phase 2 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | May 3, 2021 | September 2024 |
| NCT04015739 | Active, not recruiting | Phase 2 | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse | March 1, 2019 | January 29, 2024 |
| NCT05483933 | Active, not recruiting | Phase 1 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | August 18, 2022 | April 2025 |
| NCT02644369 | Active, not recruiting | Phase 2 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors | March 21, 2016 | December 2024 |
| NCT05397093 | Active, not recruiting | Phase 1 | ITIL-306 in Advanced Solid Tumors | August 24, 2022 | November 2039 |
| NCT05317078 | Active, not recruiting | Phase 1 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | February 28, 2023 | February 23, 2028 |
| NCT05489926 | Active, not recruiting | Phase 2 | A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure | August 16, 2022 | December 2024 |
| NCT05212779 | Active, not recruiting | Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease | October 7, 2022 | December 30, 2024 | |
| NCT03522246 | Active, not recruiting | Phase 3 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | May 14, 2018 | December 30, 2030 |
| NCT05199272 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | December 29, 2021 | March 2025 |
| NCT03393884 | Active, not recruiting | Phase 1/Phase 2 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) | September 5, 2018 | December 31, 2024 |
| NCT00850772 | Completed | Phase 3 | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer | January 2009 | August 2013 |
| NCT00861120 | Completed | Phase 2 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type | April 2009 | August 2012 |
| NCT00880360 | Completed | Phase 2 | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer | February 2007 | April 2010 |
| NCT06366997 | Completed | Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test | October 9, 2019 | May 5, 2023 | |
| NCT06086665 | Completed | The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer | December 1, 2019 | October 31, 2022 | |
| NCT00989131 | Completed | Phase 3 | Study of Paclitaxel in Patients With Ovarian Cancer | February 2009 | October 2013 |
| NCT01004380 | Completed | Phase 1 | Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer | November 2009 | October 2012 |
| NCT01068509 | Completed | Phase 2 | Ovarian Cancer Vaccine for Patients in Remission | July 2010 | April 2015 |
| NCT01091636 | Completed | Phase 2/Phase 3 | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer | March 2010 | January 10, 2020 |
| NCT01121640 | Completed | N/A | A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women | November 2009 | May 7, 2015 |
| NCT01146795 | Completed | Phase 2 | Neoadjuvant Therapy for Ovarian Cancer | May 17, 2010 | April 13, 2015 |
| NCT01164995 | Completed | Phase 2 | Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer | July 2010 | April 2023 |
| NCT01238770 | Completed | Phase 1/Phase 2 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | November 2010 | October 2015 |
| NCT01439490 | Completed | Phase 2 | FES-PET to Determine ER-expression in Epithelial Ovarian Cancer | August 2011 | February 2014 |
| NCT01442051 | Completed | N/A | Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer | September 23, 2011 | July 1, 2019 |
| NCT01447706 | Completed | Phase 2 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | October 2011 | June 2015 |
| NCT01506856 | Completed | Phase 2/Phase 3 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial | May 2010 | February 28, 2021 |
| NCT01549925 | Completed | N/A | Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand | January 2011 | September 2014 |
| NCT01617629 | Completed | Phase 2 | Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study | December 2011 | April 2014 |
| NCT01630018 | Completed | Phase 2 | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | January 2011 | June 2014 |
| NCT01649336 | Completed | Phase 1 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | July 2012 | March 2016 |
| NCT01663857 | Completed | Phase 1/Phase 2 | A Study LY2228820 for Recurrent Ovarian Cancer | July 2012 | May 11, 2018 |
| NCT01666444 | Completed | Phase 2 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | October 31, 2012 | July 31, 2016 |
| NCT00086567 | Completed | Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | December 12, 2005 | ||
| NCT01832415 | Completed | First Line Ovarian Cancer Treatment - Cohort Study | April 2013 | March 2016 | |
| NCT04716374 | Completed | Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer | January 2004 | December 2019 | |
| NCT01851109 | Completed | N/A | Prevention of Ovarian Cancer in Women Participating in Mammography | July 2008 | December 2015 |
| NCT01891344 | Completed | Phase 2 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | October 30, 2013 | September 28, 2021 |
| NCT04676334 | Completed | Phase 3 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | March 22, 2021 | March 8, 2023 |
| NCT02022917 | Completed | Phase 2 | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | March 2014 | January 2021 |
| NCT02159716 | Completed | Phase 1 | CART-meso in Mesothelin Expressing Cancers | June 2014 | November 2015 |
| NCT02312661 | Completed | Phase 1 | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer | October 5, 2015 | November 2017 |
| NCT02323568 | Completed | N/A | Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs. | December 2014 | July 2016 |
| NCT02324439 | Completed | Phase 1 | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | March 2015 | March 2021 |
| NCT02376231 | Completed | N/A | To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study | March 2013 | December 2017 |
| NCT02477202 | Completed | N/A | Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation | June 2015 | December 29, 2022 |
| NCT02480374 | Completed | Phase 1 | Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer | September 2015 | May 2017 |
| NCT04651920 | Completed | A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer | November 26, 2020 | March 26, 2022 | |
| NCT02489058 | Completed | A Study of Long-Term Responders on Olaparib | February 2016 | August 31, 2022 | |
| NCT04546373 | Completed | Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer | September 30, 2020 | July 31, 2021 | |
| NCT02606305 | Completed | Phase 1/Phase 2 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | March 2, 2016 | March 12, 2021 |
| NCT02631876 | Completed | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | March 2, 2016 | January 2020 |
| NCT02668913 | Completed | N/A | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | February 2016 | October 2020 |
| NCT04539327 | Completed | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | July 29, 2020 | July 31, 2021 | |
| NCT02728492 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | August 2013 | January 2016 |
| NCT02728830 | Completed | Early Phase 1 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | June 2016 | January 31, 2022 |
| NCT04296890 | Completed | Phase 3 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | July 23, 2020 | November 16, 2022 |
| NCT02855944 | Completed | Phase 3 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | March 1, 2017 | September 16, 2022 |
| NCT04027868 | Completed | Genomic BRCA and Extensive ovArian Cancer Testing | December 6, 2019 | November 7, 2022 | |
| NCT03332576 | Completed | Phase 1 | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | August 23, 2013 | September 9, 2019 |
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT02952521 | Completed | Ovarian Tumor Biopsies to Study Response to Treatments | January 25, 2017 | October 28, 2021 | |
| NCT03093155 | Completed | Phase 2 | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | April 3, 2017 | December 29, 2022 |
| NCT03754569 | Completed | N/A | Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer | June 1, 2018 | July 10, 2019 |
| NCT03106987 | Completed | Phase 3 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. | June 8, 2017 | February 17, 2022 |
| NCT03155451 | Completed | Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer. | August 14, 2017 | October 18, 2017 | |
| NCT03213964 | Completed | Phase 1 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | October 19, 2017 | March 10, 2021 |
| NCT02915523 | Completed | Phase 1/Phase 2 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | December 19, 2016 | April 21, 2021 |
| NCT00226915 | Completed | Phase 3 | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | April 2003 | June 2012 |
| NCT00281515 | Completed | Phase 2 | Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer | January 2006 | December 2011 |
| NCT00314678 | Completed | Phase 2 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | September 2005 | April 2007 |
| NCT00407563 | Completed | Phase 2 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | January 2007 | February 2011 |
| NCT00408603 | Completed | Phase 2 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer | December 20, 2006 | June 9, 2010 |
| NCT00421889 | Completed | Phase 1/Phase 2 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | August 2005 | February 2009 |
| NCT00428766 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer | June 2005 | December 2007 |
| NCT00490711 | Completed | Phase 2 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | July 2003 | April 2005 |
| NCT00538603 | Completed | N/A | Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) | June 2005 | June 2013 |
| NCT00561795 | Completed | Phase 2 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | September 2007 | April 2008 |
| NCT00563836 | Completed | Phase 2 | Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | November 2007 | August 2010 |
| NCT00596349 | Completed | Women Surviving Ovarian Cancer | November 2004 | February 2009 | |
| NCT00616941 | Completed | Phase 1 | Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 2008 | June 2011 |
| NCT04986371 | Not yet recruiting | Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer | August 10, 2021 | February 28, 2025 | |
| NCT04515602 | Not yet recruiting | Phase 3 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | January 2021 | January 2028 |
| NCT04889495 | Not yet recruiting | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | September 1, 2024 | May 16, 2025 | |
| NCT05187208 | Not yet recruiting | Phase 4 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | January 2022 | December 2025 |
| NCT05236686 | Not yet recruiting | N/A | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer | February 2022 | December 2025 |
| NCT05385068 | Not yet recruiting | Phase 2 | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi | June 2022 | September 2024 |
| NCT05877911 | Not yet recruiting | Phase 2 | Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy | May 2023 | April 2025 |
| NCT05991752 | Not yet recruiting | N/A | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial | November 2023 | November 2028 |
| NCT06010667 | Not yet recruiting | A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer | September 1, 2023 | August 1, 2026 | |
| NCT06277947 | Not yet recruiting | N/A | Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward | February 2024 | May 2025 |
| NCT06305299 | Not yet recruiting | Phase 1 | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | July 2024 | March 2026 |
| NCT06315270 | Not yet recruiting | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | March 20, 2024 | March 20, 2029 | |
| NCT06378905 | Not yet recruiting | Cukurova Score Validation Study | May 2024 | March 2027 | |
| NCT06386887 | Not yet recruiting | N/A | Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer | July 31, 2024 | January 1, 2026 |
| NCT06412510 | Not yet recruiting | Phase 1/Phase 2 | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | June 1, 2024 | February 10, 2025 |
| NCT03268876 | Recruiting | The INFLUENCE of Cytoreduction on PRO in EOC | March 3, 2021 | December 31, 2030 | |
| NCT04925284 | Recruiting | Phase 1 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | June 7, 2021 | October 7, 2024 |
| NCT05403554 | Recruiting | Phase 1 | A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers | April 29, 2022 | September 30, 2025 |
| NCT03321188 | Recruiting | Phase 2 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | December 15, 2017 | December 15, 2024 |
| NCT05172310 | Recruiting | Phase 1 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | June 2, 2021 | March 31, 2029 |
| NCT06395519 | Recruiting | Phase 1 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | May 2024 | December 2026 |
| NCT06223763 | Recruiting | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery | January 1, 2024 | June 1, 2024 | |
| NCT05200559 | Recruiting | Phase 1/Phase 2 | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | September 30, 2022 | December 2027 |
| NCT05984875 | Recruiting | The Immune Landscape of Epithelial Ovarian Cancer | December 20, 2022 | December 2026 | |
| NCT04282044 | Recruiting | Phase 1 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | January 8, 2021 | October 2026 |
| NCT06087289 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | April 20, 2023 | June 30, 2024 |
| NCT04001023 | Recruiting | N/A | Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia | March 9, 2017 | December 31, 2025 |
| NCT05284552 | Recruiting | Phase 2 | Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer | July 12, 2022 | December 31, 2026 |
| NCT05293496 | Recruiting | Phase 1 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | April 19, 2022 | March 2026 |
| NCT05316181 | Recruiting | Phase 3 | HIPEC for Platinum-Resistant Recurrent Ovarian Cancer | April 7, 2022 | December 31, 2029 |
| NCT05310370 | Recruiting | HRD and Resistance to PAPPi in EOC Patients | March 26, 2022 | March 26, 2025 | |
| NCT06341907 | Recruiting | Phase 2/Phase 3 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | January 1, 2024 | December 31, 2026 |
| NCT04429542 | Recruiting | Phase 1 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | June 1, 2020 | June 1, 2025 |
| NCT05874115 | Recruiting | Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer | October 17, 2019 | May 31, 2024 | |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT05870748 | Recruiting | Phase 2/Phase 3 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | July 12, 2023 | February 2026 |
| NCT06068738 | Recruiting | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer | April 14, 2023 | December 2026 | |
| NCT04516447 | Recruiting | Phase 1 | A Study of ZN-c3 in Patients With Ovarian Cancer | October 26, 2020 | February 28, 2027 |
| NCT05856409 | Recruiting | Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence | May 10, 2023 | December 31, 2025 | |
| NCT05855941 | Recruiting | Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN) | May 23, 2023 | May 2032 | |
| NCT05801276 | Recruiting | ctDNA Methylation for Detecting Ovarian Cancer | March 24, 2023 | March 24, 2026 | |
| NCT03954171 | Recruiting | N/A | Platino-resistance in Ovarian Cancer | March 6, 2020 | March 2030 |
| NCT05801263 | Recruiting | ctDNA Methylation for Epithelial Ovarian Cancer | March 24, 2023 | March 24, 2026 | |
| NCT04644289 | Recruiting | Phase 2 | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | May 5, 2022 | June 2028 |
| NCT05773859 | Recruiting | Phase 1/Phase 2 | NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer | March 17, 2023 | October 2024 |
| NCT05622890 | Recruiting | Phase 3 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | August 18, 2022 | December 31, 2023 |
| NCT05620134 | Recruiting | Phase 1/Phase 2 | Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | October 17, 2022 | February 20, 2026 |
| NCT04665635 | Recruiting | N/A | Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery | March 1, 2021 | December 2026 |
| NCT04670068 | Recruiting | Phase 1 | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | January 27, 2021 | February 2030 |
| NCT04063527 | Recruiting | Phase 3 | Phase III Trial of Stage I Ovarian Cancer After Surgery | July 20, 2012 | February 1, 2030 |
| NCT04706962 | Recruiting | Phase 1 | TH1902 in Patients With Advanced Solid Tumors | March 4, 2021 | December 2024 |
| NCT03862677 | Recruiting | Determining Prognostic Immune Markers in Patients With Ovarian Cancer | August 15, 2020 | January 31, 2027 | |
| NCT04152499 | Recruiting | Phase 1/Phase 2 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | February 28, 2020 | December 2025 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT05563272 | Recruiting | Phase 2 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors | June 6, 2023 | December 29, 2025 |
| NCT05429970 | Recruiting | N/A | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | June 17, 2022 | June 17, 2025 |
| NCT06085456 | Recruiting | Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study | September 1, 2021 | June 30, 2024 | |
| NCT02947152 | Terminated | Phase 1 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | December 1, 2016 | September 14, 2017 |
| NCT03933813 | Terminated | Phase 1/Phase 2 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | July 29, 2019 | November 22, 2021 |
| NCT02943317 | Terminated | Phase 1 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | October 2016 | December 28, 2018 |
| NCT02900560 | Terminated | Phase 2 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | December 20, 2016 | May 27, 2021 |
| NCT02834975 | Terminated | Phase 2 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | December 22, 2016 | December 1, 2022 |
| NCT04493619 | Terminated | Phase 1/Phase 2 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | August 11, 2020 | April 25, 2022 |
| NCT04562298 | Terminated | Phase 1 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer | October 21, 2020 | June 7, 2022 |
| NCT02012192 | Terminated | Phase 1/Phase 2 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | July 4, 2014 | December 4, 2017 |
| NCT01840943 | Terminated | Phase 3 | A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | June 2013 | August 2014 |
| NCT04726332 | Terminated | Phase 1 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | February 10, 2021 | May 2, 2024 |
| NCT01773889 | Terminated | Phase 2 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer | June 2009 | June 2011 |
| NCT01681368 | Terminated | Phase 2 | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | August 15, 2012 | April 30, 2014 |
| NCT00968799 | Terminated | N/A | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | February 2008 | December 2012 |
| NCT01521143 | Terminated | Phase 2 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment | January 2012 | March 2015 |
| NCT05215496 | Terminated | Phase 1 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | May 10, 2022 | May 1, 2023 |
| NCT05261490 | Terminated | Phase 1/Phase 2 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | August 1, 2022 | February 15, 2024 |
| NCT01202890 | Terminated | Phase 1 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | September 2010 | May 2012 |
| NCT01095367 | Terminated | N/A | Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer | April 2010 | January 2014 |
| NCT01018563 | Terminated | Phase 2 | An Open Label Extension Study of the Efficacy of MORAb-003 | January 13, 2010 | March 5, 2013 |
| NCT00889733 | Terminated | Phase 1/Phase 2 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer | February 2007 | December 2009 |
| NCT03100006 | Terminated | Phase 1/Phase 2 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | February 22, 2017 | April 17, 2020 |
| NCT03824704 | Terminated | Phase 2 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | August 23, 2019 | August 24, 2020 |
| NCT04864431 | Unknown status | N/A | Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer | January 12, 2022 | December 31, 2023 |
| NCT03742388 | Unknown status | A Genomic Analysis of Evolution of Epithelia Ovarian Tumors | November 10, 2018 | December 23, 2020 | |
| NCT04983550 | Unknown status | Phase 2 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | September 2021 | January 2024 |
| NCT03742856 | Unknown status | A Multi-omics Study of Epithelial Ovarian Cancer | November 10, 2018 | November 23, 2020 | |
| NCT04846842 | Unknown status | Phase 2 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | July 1, 2021 | July 1, 2023 |
| NCT04651946 | Unknown status | Phase 2 | Cell-free DNA Methylation for Epithelial Ovarian Cancer | November 26, 2020 | November 26, 2022 |
| NCT04651933 | Unknown status | A Training Set for the HRD Model in EOC | November 26, 2020 | November 26, 2022 | |
| NCT04620954 | Unknown status | Phase 1/Phase 2 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | October 7, 2020 | July 2022 |
| NCT04555473 | Unknown status | Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids | May 12, 2020 | May 4, 2023 | |
| NCT02595021 | Unknown status | Phase 2 | Total/Subtotal Colectomy in Ovarian Cancer | July 2015 | December 2018 |
| NCT02681432 | Unknown status | Phase 3 | Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer | January 2012 | December 2019 |
| NCT04504110 | Unknown status | Phase 2 | 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings | August 5, 2020 | August 2021 |
| NCT04473339 | Unknown status | Phase 3 | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation | August 1, 2020 | December 30, 2023 |
| NCT04421547 | Unknown status | Phase 3 | Efficacy of Letrozole in Recurrent Ovarian Cancer | June 1, 2020 | December 1, 2022 |
| NCT04279509 | Unknown status | N/A | Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) | May 29, 2019 | May 2022 |
| NCT04101760 | Unknown status | Phase 3 | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer | October 1, 2019 | October 1, 2020 |
| NCT02859038 | Unknown status | Phase 3 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | August 2016 | June 2023 |
| NCT04191252 | Unknown status | Genetic Mutation in Epithelial Ovarian Cancer | December 19, 2019 | January 1, 2023 | |
| NCT03371693 | Unknown status | Phase 3 | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer | September 30, 2017 | March 30, 2023 |
| NCT03373058 | Unknown status | Phase 3 | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery | October 15, 2019 | July 1, 2023 |
| NCT04190667 | Unknown status | Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer | December 7, 2019 | December 7, 2022 | |
| NCT03180177 | Unknown status | Phase 3 | Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer | March 1, 2018 | July 1, 2022 |
| NCT03622385 | Unknown status | Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer | February 19, 2019 | March 8, 2022 | |
| NCT03692637 | Unknown status | Early Phase 1 | Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer | March 2019 | November 2021 |
| NCT05310357 | Unknown status | Chromosomal Instability in Ovarian Cancer | March 26, 2022 | March 26, 2024 | |
| NCT03740464 | Unknown status | Phase 3 | Long-acting G-CSF for Febrile Neutropenia | November 10, 2018 | November 10, 2023 |
| NCT01680575 | Unknown status | Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer | September 2012 | May 2018 | |
| NCT01000896 | Withdrawn | Phase 1 | Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | January 2010 | March 2011 |
| NCT03607955 | Withdrawn | Phase 1 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | June 30, 2021 | August 31, 2029 |
| NCT02487849 | Withdrawn | Phase 2 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma | August 2016 | August 2016 |